Skip to main content
. 2020 Aug 11;12:230. doi: 10.3389/fnagi.2020.00230

Figure 5.

Figure 5

(A–I) Western blot analysis of indicated proteins from contralateral and ipsilateral striata of 6-OHDA-lesioned rats treated with vehicle or rapamycin. (A,B) p-Ser845-GluA1 and p-Thr202/Tyr204-ERK42 protein levels in dopamine (DA) denerveted rats treated with vehicle (n = 5) or rapamycin (n = 4). (C,D) p-Ser240/244-S6 and TH protein levels (n = 5/treatment). (E,F) Protein expression of the subunits GluA1 and GluA2/3 of AMPA-type glutamate receptors in vehicle (n = 5) and rapamycin (n = 4) treated rats lesioned with 6-OHDA. (G,H) GluN1 and GluN2A NMDA receptor subunit levels in 6-OHDA vehicle or 6-OHDA rapamycin-treated rats (n = 5/treatment). (I) Expression of the GluN2B subunit in vehicle (n = 5) or rapamycin (n = 4) treated rats lesioned with 6-OHDA. (J–R) Western blot analysis of indicated proteins from contralateral and ipsilateral striata of sham-operated rats treated with vehicle or rapamycin (n = from 3 to 5/treatment). (J–L) Phosphorylation levels of GluA1 at Ser845, ERK42 at Thr202/Tyr204, and S6 at Ser240/244. (M) Tyrosine hydroxylase protein levels in contralateral and ipsilateral striata from sham-operated group. Protein expression of (N,O) AMPA (GluA1 and GluA2/3) and (P–R) NMDA glutamate receptor subunits (GluN1, GluN2A, and GluN2B). All data are expressed as mean ± SEM. Statistical significance was determined by two-way ANOVA, followed by Bonferroni multiple-comparisons test, ##p < 0.01 for TH protein levels. For phospho-S6 levels (panels C,L), two-way ANOVA returned a significant treatment effect ($$p < 0.001 and $p < 0.05 for panels C,L, respectively).